NewAmsterdam Pharma (NAMS) Institutional Ownership $18.86 +0.14 (+0.75%) (As of 07/26/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for NewAmsterdam Pharma (NASDAQ:NAMS)CurrentInstitutional OwnershipPercentage89.89%Number ofInstitutional Buyers(last 12 months)18TotalInstitutional Inflows(last 12 months)$295.34MNumber ofInstitutional Sellers(last 12 months)0 Get NAMS Insider Trade Alerts Want to know when executives and insiders are buying or selling NewAmsterdam Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NAMS Institutional Buying and Selling by Quarter Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. NewAmsterdam Pharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/12/2024 Rosalind Advisors Inc.10,123$194K0.1%N/A0.011% 5/29/2024Opaleye Management Inc.315,388$7.46M1.6%+18.8%0.351% 5/17/2024Artal Group S.A.800,000$18.92M0.5%N/A0.896% 5/16/2024Janus Henderson Group PLC636,231$15.02M0.0%N/A0.713% 5/15/2024Baker BROS. Advisors LP96,827$2.29M0.0%N/A0.108% 5/15/2024Affinity Asset Advisors LLC286,200$6.77M0.8%+129.0%0.321% Get the Latest News and Ratings for NAMS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. 5/14/2024StemPoint Capital LP80,334$1.90M0.5%N/A0.090% 5/7/2024TimesSquare Capital Management LLC228,616$5.41M0.1%N/A0.256% 5/2/2024Jennison Associates LLC930,851$22.02M0.0%N/A1.043% 4/10/2024Yarbrough Capital LLC23,960$567K0.0%N/A0.027% 3/7/2024Fcpm Iii Services B.V.11,831,461$132.16M39.2%N/A14.373% 2/15/2024Opaleye Management Inc.265,388$2.96M0.8%N/A0.325% 2/15/2024Parkman Healthcare Partners LLC300,750$3.36M0.5%+20.8%0.369% 2/1/2024Wolverine Asset Management LLC8,694$97K0.0%+197.2%0.011% 11/15/2023Affinity Asset Advisors LLC125,000$1.16M0.3%+25.0%0.153% 11/14/2023Schonfeld Strategic Advisors LLC64,700$598K0.0%+12.9%0.079% 11/13/2023Wolverine Asset Management LLC2,925$27K0.0%N/A0.004% 8/21/2023Affinity Asset Advisors LLC100,000$1.19M0.4%N/A0.123% 8/15/2023RA Capital Management L.P.9,000,000$107.01M2.0%+125.0%11.035% 8/15/2023Bain Capital Life Sciences Investors LLC10,473,913$124.54M12.8%+26.2%12.842% 8/10/2023Monashee Investment Management LLC95,000$1.13M0.3%N/A0.116% 8/4/2023Maven Securities LTD25,000$297K0.0%N/A0.031% 7/19/2023 Medicxi Ventures Management Jersey Ltd2,869,565$34.12M9.6%+43.5%3.518% 7/14/2023Venture Visionary Partners LLC10,000$119K0.0%N/A0.012% 5/9/2023GMT Capital Corp1,083,800$14.37M0.6%+8.4%6.106% 5/8/2023Wolverine Asset Management LLC4,819$64K0.0%N/A0.027% 2/14/2023RA Capital Management L.P.4,000,000$43.60M0.9%N/A22.535% 2/3/2023Frazier Life Sciences Management L.P.9,341,551$101.82M6.3%N/A52.628% 2/3/2023GMT Capital Corp1,000,000$10.90M0.5%N/A5.634% 1/31/2023 Medicxi Ventures Management Jersey Ltd2,000,000$21.80M9.2%N/A11.268% (Data available from 1/1/2016 forward) NAMS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NAMS shares? During the previous two years, 22 institutional investors and hedge funds held shares of NewAmsterdam Pharma. The most heavily invested institutionals were Fcpm Iii Services B.V. ($132.16M), Bain Capital Life Sciences Investors LLC ($124.54M), RA Capital Management L.P. ($107.01M), Frazier Life Sciences Management L.P. ($101.82M), Medicxi Ventures Management Jersey Ltd ($34.12M), Jennison Associates LLC ($22.02M), and Artal Group S.A. ($18.92M).Learn more on NAMS's institutional investors. What percentage of NewAmsterdam Pharma stock is owned by institutional investors? 89.89% of NewAmsterdam Pharma stock is owned by institutional investors. Learn more on NAMS's institutional investor holdings. Which institutional investors have been buying NewAmsterdam Pharma stock? Of the 22 institutional investors that purchased NewAmsterdam Pharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Fcpm Iii Services B.V. ($11.83M), Frazier Life Sciences Management L.P. ($9.34M), RA Capital Management L.P. ($9M), Medicxi Ventures Management Jersey Ltd ($2.87M), Bain Capital Life Sciences Investors LLC ($2.17M), GMT Capital Corp ($1.08M), and Jennison Associates LLC ($930.85K). How much institutional buying is happening at NewAmsterdam Pharma? Institutional investors have bought a total of 39,911,459 shares in the last 24 months. This purchase volume represents approximately $485.09M in transactions. Related Companies: Elanco Animal Health Major Shareholders Krystal Biotech Major Shareholders Organon & Co. Major Shareholders Apellis Pharmaceuticals Major Shareholders Avidity Biosciences Major Shareholders Crinetics Pharmaceuticals Major Shareholders Immunovant Major Shareholders Arcellx Major Shareholders Xenon Pharmaceuticals Major Shareholders Merus Major Shareholders This page (NASDAQ:NAMS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.